Radiology Research and Practice · 2020 · 19 citations · 23 references
MedicineOncologyChemotherapyCutaneous OncologyMetastasisLiver MetastasisMalignant NeoplasmsMelanoma PharmacotherapyMetastatic Cancer ManagementMetastatic Disease ManagementUveal MelanomaClavien-dindo ClassificationCox RegressionKaplan-meier Confidence IntervalsMelanoma Liver MetastasisMetastatic Uveal MelanomaRecist CriteriaTumor Response EvaluationUveal Melanoma Metastasis
Introduction . Percutaneous hepatic perfusion with melphalan (PHP-M) for hepatic metastasis of uveal melanoma (LMUM) achieves high local response rates, but the individual clinical benefit is poorly defined. We aimed to determine cofactors of response and clinical outcomes including the probability of long-term (5-years) overall survival (OS) in PHP-M-treated patients with LMUM. Patients and Methods . We retrospectively reviewed clinicopathological, radiological, and outcome data of 19 patients with unresectable LMUM treated with 43 PHP-M (median 2 PHP-M) between 2014 and 2019. Tumor response and adverse events were evaluated using RECIST 1.1 and the Clavien–Dindo classification. Kaplan–Meier methods and Cox regression hazard proportional models were used. Results . Of 19 patients, 10 (53%) achieved a partial response (PR) and 9 (47%) had stable disease (SD). There was no progressive disease (PD) and no adverse events exceeding Clavien–Dindo grade IV. Median OS was 16.7 months after the first PHP-M treatment and 26.4 months after initial diagnosis. Low hepatic tumor volume (median of 10 mL vs. 150 mL) was an independent predictor of favorable OS (hazard ratio (95% confidence interval): 0.190 (0.041, 0.893); <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.05</mml:mn></mml:math>), and female patients were at a lower risk compared with males (0.146 (0.017, 1.240)). Estimates of the overall survival were 0.213 (0.0449, 1) from first imaging (95% confidence interval) to 5 years and 0.793 (0.609, 1) and 0.604 (0.380, 0.960) for 1 and 2 years after chemosaturation, respectively. Discussion . PHP-M for nonresectable LMUV provides a safe and locally efficient liver-directed procedure that offers patients a chance for long-term OS, especially for patients with a low hepatic tumor burden.
23
Classification of Surgical Complications
Daniel Dindo, Nicolas Demartines, Pierre-Alain Clavien · Annals of Surgery · 2004 · 30.9K citations · Full text
Medicine, Surgery, General Surgery +13
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text